Kyowa Kirin links with Ultragenyx for first-in-class XLH therapy

Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).